Page 12 - ஆயோக் உறுப்பினர் ஆரோக்கியம் டாக்டர் வ்க் பால் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

After Pfizer, Serum Institute seeks indemnity over COVID-19 vaccine: Sources ANI | Updated: Jun 03, 2021 10:38 IST New Delhi [India], June 3 (ANI): Amid discussions over possible legal protection to foreign vaccine manufacturers Pfizer and Moderna over their COVID-19 jabs in India, the Serum Institute of India (SII) has also sought protection against liabilities, sources said on Thursday. Not just Serum Institute of India, all the vaccine companies should get indemnity protection against liabilities if foreign companies are granted the same, sources added. Earlier last year, SII CEO Adar Poonawala had advocated for indemnity for all vaccine manufacturers. We need to have the government indemnify manufacturers, especially vaccine manufacturers, against all lawsuits. Frivolous claims come up and you see in the media something being blown out of proportion. The government needs to step in with the right messaging, he had said.

United statesUnited kingdomNew delhiAdar poonawalaNirmalk gangulySerum institute of indiaAayog member health dr vk paulWorld health organisationSerum instituteDrugs controller generalEmergency useWorld healthSerum institute of indiaCovid 19ஒன்றுபட்டது மாநிலங்களில்ஒன்றுபட்டது கிஂக்டம்